Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Deflox · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| First Deflox®, Then Cataflam DD® | EXPERIMENTAL | Participants received single oral dose of Deflox® 50 milligrams (mg) tablet in Treatment Period 1 followed by a single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between the Treatment Periods 1 and 2. |
| First Cataflam DD®, Then Deflox® | EXPERIMENTAL | Participants received single oral dose of Cataflam DD® 50 mg tablet in Treatment Period 1 followed by single oral dose of Deflox® 50 mg tablet in Treatment Period 2 under fasting condition. A wash-out period of 7 days was maintained between Treatment Periods 1 and 2. |
| Name | Type | Description |
|---|---|---|
| Deflox® | DRUG | Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions. |
| Cataflam DD® | DRUG | Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions. |
Inclusion Criteria: * Participants who have a body weight within 55-95 kilograms (kg) and body mass index (BMI) within the range 18.0-27.0 kilogram/meter square (kg/m2) (inclusive) * Participant has given written informed consent before any study-related activities are carried out - Participants wi...
Deflox is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development. The only completed trial evaluated Deflox tablets for bioequivalence in healthy participants. Deflox is not approved and remains in clinical development.
Deflox is being developed by Merck KGaA, a company traded under the ticker MKGAF. The developer is responsible for the ongoing clinical development of this investigational small molecule.
Deflox is in Phase 1 clinical development. The single trial listed for Deflox is a Phase 1 study that has been completed. Deflox is an investigational drug and has not been approved.
Deflox has one clinical trial, NCT04132583, titled "Deflox Tablets Bioequivalence (BE) Trial." This Phase 1 study enrolled 16 healthy volunteers in Mexico and has been completed. The trial was randomized and controlled.
Deflox is not FDA approved. It is an investigational small molecule currently in Phase 1 clinical development. The available data shows one completed Phase 1 trial, but no approval status has been established.